|1.||Thorpe, Philip E: 8 articles (01/2015 - 09/2007)|
|2.||Watkins, Linda: 4 articles (01/2015 - 03/2008)|
|3.||Gerber, David E: 4 articles (01/2015 - 08/2011)|
|4.||Shan, Joseph S: 3 articles (07/2015 - 11/2011)|
|5.||Yin, Yi: 3 articles (10/2013 - 11/2009)|
|6.||He, Jin: 3 articles (11/2009 - 09/2007)|
|7.||Stopeck, Alison T: 2 articles (07/2015 - 11/2011)|
|8.||Öz, Orhan K: 2 articles (04/2015 - 01/2015)|
|9.||Sun, Xiankai: 2 articles (04/2015 - 01/2015)|
|10.||Kumar, Amit: 2 articles (04/2015 - 01/2015)|
|1.||Lung Neoplasms (Lung Cancer)
09/01/2007 - "Bavituximab, a chimeric version of 2aG4 in clinical trials, has the potential to enhance the therapeutic efficacy of radiation therapy in lung cancer patients."
08/01/2011 - "Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment."
01/01/2015 - "Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts."
|2.||Breast Neoplasms (Breast Cancer)
07/01/2015 - "Bavituximab in combination with paclitaxel is well tolerated for treatment of patients with metastatic breast cancer with promising results observed in terms of clinical RRs and PFS. "
07/01/2015 - "We conducted a phase I clinical trial of bavituximab in combination with paclitaxel in patients with HER2-negative metastatic breast cancer. "
07/01/2015 - "A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer."
10/01/2013 - "These data suggest that phosphatidylserine is responsible for the expansion of MDSCs and M2-like TAMs in tumors, and that bavituximab, a phosphatidylserine-targeting antibody currently in clinical trials for cancer, could reverse this process and reactivate antitumor immunity."
11/01/2011 - "This phase I study assessed the safety and pharmacokinetics of bavituximab in patients with advanced solid tumors. "
11/01/2011 - "Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors."
03/01/2008 - "Immunohistochemical studies showed that the bavituximab was labeling the tumor vascular endothelium. "
03/01/2008 - "Biodistribution studies confirmed the specific localization of bavituximab to the tumors. "
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
08/01/2011 - "This article summarizes the preclinical development and clinical experience with bavituximab in non-small-cell lung cancer."
08/01/2011 - "Phase II trials of bavituximab in combination with chemotherapy for the first- and second-line treatment of advanced non-small-cell lung cancer are currently ongoing. "
01/01/2015 - "Bavituximab is a chimeric monoclonal antibody with immune modulating and tumor-associated vascular disrupting properties demonstrated in models of non-small cell lung cancer (NSCLC). "
11/01/2014 - "This study evaluated bavituximab in combination with paclitaxel and carboplatin in patients with previously untreated, locally advanced or metastatic non-small-cell lung cancer (NSCLC). "
11/01/2014 - "Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer."
|5.||Pancreatic Neoplasms (Pancreatic Cancer)
07/01/2013 - "In two studies, nimotuzumab, a monoclonal antibody against epidermal growth factor receptor (EGFR) (Abstract #4009) and bavituximab, a monoclonal antibody against phosphatidylserine (Abstract #4054) are tested in combination with gemcitabine in patients with advanced pancreatic cancer. "
|3.||Epidermal Growth Factor Receptor (EGF Receptor)
|6.||beta 2-Glycoprotein I (Apolipoprotein H)
|10.||1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)